CBT for Insomnia in Primary Brain Tumor Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04919993|
Recruitment Status : Active, not recruiting
First Posted : June 9, 2021
Last Update Posted : May 20, 2022
|Condition or disease||Intervention/treatment||Phase|
|Primary Brain Tumor PBT||Behavioral: Cognitive Behavioral Therapy-Insomnia||Not Applicable|
The present study design is a pilot within-subjects pre-/post-evaluation of feasibility, acceptability, and preliminary efficacy of the Cognitive Behavioral Therapy for Insomnia (CBT-I) intervention for primary brain tumor patients. In this study, participants will be asked to do the following things:
- Meet with a trained interventionist six times (biweekly) for group CBT-I sessions via Zoom, lasting 90 minutes each. Participants will be asked to only use first names and will complete weekly sleep diaries as part of the intervention.
- Complete ~20-minute online surveys before the program, immediately after the program (6 weeks), and at follow-up (3 months). Questions will ask about subjective sleep, fatigue, mood, and quality of life. The follow-up time point will also ask about the patient's satisfaction with the CBT-I program.
- Complete a brief (15 minute) cognitive evaluation before and immediately following the program.
- Wear a wrist-worn actigraphy monitor one week prior to the 6-week CBT-I intervention and one week following completion of the intervention.
- Patients currently receiving regular blood draws as part of their care at Massey Cancer Center will have an IL-6 added to their regular blood draw. THose who are not receiving regular blood draws as part of their standard of care OR those who are not patients at Massey Cancer Center will forego this part of the intervention.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Phase IIa Proof-of-Concept Trial|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Cognitive Behavioral Therapy for Insomnia in Primary Brain Tumor Patients|
|Actual Study Start Date :||June 1, 2021|
|Estimated Primary Completion Date :||January 31, 2023|
|Estimated Study Completion Date :||January 31, 2023|
Experimental: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Group intervention; topics include psychoeducation about sleep, sleep restriction, stimulus control, relaxation strategies, and cognitive restructuring.
Behavioral: Cognitive Behavioral Therapy-Insomnia
Other Name: CBT-I
- Feasibility for CBT-I as measured by the rates of participant screening, eligibility, and consent [ Time Frame: 12 months ]Determine how many patients consent to screening after referral to the program, how many patients are eligible for the program after being screened, and how many consent/enroll in the program if eligible.
- Attendance at CBT-I sessions [ Time Frame: 6 weeks ]Percent of sessions attended by consented participants
- Post-session assessment completion [ Time Frame: 2 months ]Percent of post-session surveys completed by participants immediately after the intervention
- Follow-up assessment completion [ Time Frame: 5 months ]Percent of follow-up surveys completed by participants three months after the intervention
- Program Satisfaction as measured by participant responses to researcher-developed questions (e.g., How satisfied were you with the program overall?) measured on a Likert scale [ Time Frame: 7 months ]Program satisfaction questions are measured on a 10-point Likert scale with 1 being not at all satisfied and 10 being very much satisfied. Higher scores indicate greater program satisfaction.
- Objective Sleep [ Time Frame: 7 months ]Total sleep time gathered by the participant from a wrist-worn Actigraph
- Sleep Efficiency [ Time Frame: 7 months ]Percent of time spent in bed / time asleep gathered by the participant from a wrist-worn Actigraph
- Subjective Sleep [ Time Frame: 7 months ]Total sleep time gathered from a participant-reported sleep diary
- Subjective Insomnia [ Time Frame: 7 Months ]Determine the degree of participant insomnia using the Insomnia Severity Index, a brief self-report questionnaire measured on a 5-point Likert scale (0 = None, 4 = Very Severe). Higher scores indicate greater subjective insomnia.
- Subjective Sleep Disturbance [ Time Frame: 7 Months ]Determine the degree of participant sleep disturbance using the Pittsburgh Sleep Quality Index, a brief self-report questionnaire. Higher scores indicate greater global sleep disturbance.
- Napping [ Time Frame: 7 Months ]Request that participants self report how many hours a day they nap on average using one self-report question (During the past month, how many hours did you nap during a typical day?)
- Fatigue [ Time Frame: 7 Months ]Determine participants' level of fatigue using the Brief Fatigue Inventory, a self-report questionnaire measured on a 11-point Likert scale (0 = No Fatigue/Does Not Interfere; 10 = As Bad as You Can Imagine/Completely Interferes). Higher scores indicate greater symptoms of fatigue.
- Depression [ Time Frame: 7 Months ]Determine the extent of depressive symptoms using the Patient Health Questionnaire-9, a brief-self report questionnaire measured on a 4-point Likert scale (0 = Not at All; 3 = Nearly Everyday) Higher scores indicate greater symptoms of depression.
- Anxiety [ Time Frame: 7 Months ]Determine the extent of anxiety symptoms using the Generalized Anxiety Disorder-7, a self-report questionnaire measured on a 4-point Likert scale (0 = Not at All; 3 = Nearly Everyday). Higher scores indicate greater symptoms of anxiety.
- Death Anxiety [ Time Frame: 7 Months ]Determine the level of participant's death anxiety using the Death and Dying Distress Scale, a self-report questionnaire measured on a 6-point Likert scale (0 = Not Distress; 5 = Extreme Distress). Higher scores indicate greater symptoms of death anxiety.
- Subjective Quality of Life as measured by participants' responses on the European Organization Research and Treatment of Cancer - Quality of Life - Cancer 30 (EORTC-QoL-C30) form. [ Time Frame: 7 Months ]Determine participants' level of quality of life using the EORTC-QoL-C30, a self-report questionnaire measured on a 4-point Likert scale (1 = Not at All; 4 = Very Much). Higher scores indicate lower overall quality of life.
- Inflammation [ Time Frame: 7 Months ]Determine the level of inflammation as measured by the amount of Cytokine Interleukin-6 (IL-6) in the participant's blood; only participants receiving regular blood draws as part of their routine will have this data
- Processing Speed [ Time Frame: 7 months ]Participants' speed of thinking will be assessed by administering the Trail Making Test A, a neuropsychological assessment tool
- Executive Function [ Time Frame: 7 months ]Measure executive functioning by administering the Trail Making Test B, a neuropsychological assessment tool
- Language Fluency [ Time Frame: 7 months ]Participants' language fluency will be measured using the Controlled Oral Word Association Test, a neuropsychological assessment tool
- Learning/Memory [ Time Frame: 7 months ]Participants' ability learn/ memory will be assessed by administering the Hopkins Verbal Learning Test, a neuropsychological assessment tool
- Sociodemographics [ Time Frame: 7 months ]Participants are requested to self-report on their age, gender identity, race/ethnicity, and level of education
- Primary Brain Tumor Characteristics [ Time Frame: 7 months ]Information on participants' tumor diagnosis, treatment history, and medications will be from the participants' medical charts to determine brain tumor characteristics
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04919993
|United States, Virginia|
|Virginia Commonwealth University|
|Richmond, Virginia, United States, 23298|
|Principal Investigator:||Ashlee Loughan, PhD||Virginia Commonwealth University|